Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C Co-infected, treatment-experienced HIV patients

HIV Clinical Trials

Volumn 10, Issue 4, 2009, Pages 269-275

  Pérez Elías, María ^a   Gatell, Jose ^b   Flores, Juan ^c   Santos, Jesús ^d   Vera Médez, Francisco ^e   Clotet, Bonaventura ^f   Moreno, Ana ^a   Pérez Molina, Jose Antonio ^a   Vendrell, Belén ^g   Serrano, Oscar ^g  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b H Clinic i Provincial   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d H Virgen de la Victoria   (Spain)

^e Hospital Universitario Santa Maria del Rosell   (Spain)

^f Germans Trias i Pujol Foundation   (Spain)

^g Hospital Ramón y Cajal ^*

Author keywords

ARV experienced; Boosted atazanavir; HBV; HCV; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE JAUNDICE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR; RNA, VIRAL;

EID: 70349106358     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1004-269     Document Type: Article

References (23)

1. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defi c Syndr. 2001;27:426-431.
2. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
3. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36-43.
4. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
6. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
7. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90-97.
8. Havlir DV, O Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004;38:1599-1604.
9. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-2614.
10. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
11. Mallolas J, Podzamczer D, Domingo P, et al. Effi cacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB117LB.
12. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week effi cacy and safety results of the CASTLE study. Lancet. Epub August 2, 2008. DOI:10.1016/S0140-6736 (08)61081-61088
13. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother. 2004;38:1664-1674.
14. 15. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defi c Syndr. 2003;32:259-267.
15. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defi c Syndr. 2001;27:316-318.
16. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodefi ciency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis. 1995;172:1503-1508.
17. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277-2284.
18. Lopinavir/ritonavir (LPV/r) Safety, tolerability and effi cacy and liver safety in HC and/or Hep B-infected patients: review of Kaletra trials. In: Program and abstracts of the XV World AIDS Conference; 2004; Bangkok. Abstract B3285.
19. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fi xed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defi c Syndr. 2004;36:1011-1019.
20. Youle M, Gerstoft J, Fox Z, et al. The fi nal 48 week analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and effi cacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin2 trial. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment; 2003. Poster LB23.
21. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-na ve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. Epub August 2, 2008. DOI:10.1016/S0140-6736(08)61081-8.
22. Pineda JA, Palacios R, Rivero A, et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother. 2006;57:1016-1017.
23. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29:41-48.